Literature DB >> 21288122

Early diagnoses and psychotherapeutic medication treatment experiences of a cohort of children under 6 years old who received antipsychotic treatment in Florida's Medicaid program.

Robert J Constantine1, Rajiv Tandon, Marie McPherson, Ross Andel.   

Abstract

OBJECTIVE: To describe the diagnostic characteristics and psychotherapeutic medication experiences of a cohort of children who received antipsychotic treatment before their sixth birthday.
METHODS: Children enrolled in Florida's Medicaid program were identified as having initiated an index episode of antipsychotic treatment before their sixth birthday. The characteristics of these children were compared to nonrecipients who were less than 6 years old on January 1, 2004. An index episode is described as the filling of at least two consecutive antipsychotic prescriptions with a gap no greater than 15 days between the last day supplied of the first prescription and the fill date of the second prescription. We describe the diagnoses and psychotherapeutic medication experiences of these children during the 365 days before the start of their index episodes (preindex periods) and during the 365 days immediately after the start of their index episodes (index periods).
RESULTS: Five hundred twenty-eight recipients were identified. Recipients were more likely than nonrecipients to be male, to be older, and to have a supplemental security income enrollment status. Recipients were exposed to psychotherapeutic medications at very early ages. Four hundred thirty-nine (83%) had already been treated with some psychotherapeutic medication during their preindex periods. Of these children, 303 (69%) filled at least one prescription for an antipsychotic medication. Index antipsychotic episodes were often lengthy. Mean ± standard deviation and median episode lengths were 266.9 ± 286.8 and 174 days, respectively. During the index periods half of the children were found to have attention-deficit/hyperactivity disorder and 18% had disruptive behavior disorders. Treatment during these periods included other classes of psychotherapeutic medications for 73% of children. Nearly 30% (29.6%) received two or more classes of medications in addition to antipsychotics.
CONCLUSIONS: We found a large group of very young children who were persistently treated with antipsychotic medications. This early and extensive exposure is a cause for concern.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21288122     DOI: 10.1089/cap.2010.0068

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  6 in total

1.  Early-life risperidone enhances locomotor responses to amphetamine during adulthood.

Authors:  Bobbie Lee Stubbeman; Clifford J Brown; Justin R Yates; Mark E Bardgett
Journal:  Eur J Pharmacol       Date:  2017-07-14       Impact factor: 4.432

2.  The effects of prior authorization policies on medicaid-enrolled children's use of antipsychotic medications: evidence from two mid-Atlantic states.

Authors:  Bradley D Stein; Emily Leckman-Westin; Edward Okeke; Deborah M Scharf; Mark Sorbero; Qingxian Chen; Ka Ho Brian Chor; Molly Finnerty; Jennifer P Wisdom
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-08-21       Impact factor: 2.576

3.  Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012.

Authors:  Christian J Bachmann; Thomas Lempp; Gerd Glaeske; Falk Hoffmann
Journal:  Dtsch Arztebl Int       Date:  2014-01-17       Impact factor: 5.594

4.  Delayed yet persistent effects of daily risperidone on activity in developing rats.

Authors:  Rachel M Stevens; Matthew A Gannon; Molly S Griffith; Mark E Bardgett
Journal:  Behav Pharmacol       Date:  2016-08       Impact factor: 2.293

5.  Early-life risperidone administration alters maternal-offspring interactions and juvenile play fighting.

Authors:  Matthew A Gannon; Clifford J Brown; Rachel M Stevens; Molly S Griffith; Cecile A Marczinski; Mark E Bardgett
Journal:  Pharmacol Biochem Behav       Date:  2015-01-17       Impact factor: 3.533

6.  Independent review of social and population variation in mental health could improve diagnosis in DSM revisions.

Authors:  Helena B Hansen; Zoe Donaldson; Bruce G Link; Peter S Bearman; Kim Hopper; Lisa M Bates; Keely Cheslack-Postava; Kristin Harper; Seth M Holmes; Gina Lovasi; Kristen W Springer; Julien O Teitler
Journal:  Health Aff (Millwood)       Date:  2013-04-24       Impact factor: 6.301

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.